奥沙利铂或替吉奥联合紫杉醇治疗进展期胃癌的临床疗效及安全性评价

Clinical study on efficacy and safety of oxaliplatin or tegafur combined with paclitaxel in the treatment of advanced gastric carcinoma

目的评价奥沙利铂或替吉奥联合紫杉醇治疗进展期胃癌的临床疗效及安全性。方法将58例进展期胃癌患者随机分为奥沙利铂联合紫杉醇组30例和替吉奥联合紫杉醇组28例。奥沙利铂联合紫杉醇组给予奥沙利铂130mg·m^-2,第1天,静脉滴注＋紫杉醇135 mg·m^-2,第1,8天,静脉滴注;替吉奥联合紫杉醇组给予替吉奥80 mg·m^-2·d^-1,第1-14天,口服＋紫杉醇135mg·m^-2,第1,8天,静脉滴注。28 d为1个化疗周期,2组患者至少接受2个周期以上的化疗,比较2组患者的临床疗效和不良反应发生率。结果化疗2个周期后,奥沙利铂联合紫杉醇组与替吉奥联合紫杉醇组的客观缓解率分别为33.3%和35.7%,2组比较差异无统计学意义（P〉0.05）;替吉奥联合紫杉醇组Ⅲ-Ⅳ级腹泻显著低于奥沙利铂联合紫杉醇组（P〈0.05）。结论奥沙利铂联合紫杉醇与替吉奥联合紫杉醇治疗进展期胃癌的临床疗效无明显差异,但替吉奥联合紫杉醇组患者不良反应发生率较低。

Objective To evaluate the clinical efficacy of oxaliplatin or tegafur combined with paclitaxel in the treatment of advanced gastric carcinoma.Methods Fifty-eight patients with advanced gastric carcinoma were enrolled in our hospital and divided in two groups.Thirty patients in OP group received the chemotherapy regimen of oxaliplatin 130mg·m^-2on day 1,and paclitaxel 135 mg·m^-2on day 1 and 8 through intravenous drip and the other 28 subjects in SP group received chemotherapy regimen of oral tegafur 80 mg · m-2·d^-1on day 1 to day 14 plus paclitaxel 135 mg · m^-2on day 1 and 8 through intravenous drip.The data of clinical efficacy and adverse reactions of the two groups were compared after more than 2 cycles of chemotherapy,twenty-eight days was a cycle.Results The data of objective response rate were 33.3% and35.7% in OP and SP group,respectively,which indicated that there was no statistical difference between the two groups（P〉0.05）; but the risk of grade Ⅲ to Ⅳ diarrhea patients in the OP group was much higher than that in SP group（P〈0.05）.Conclusion The clinical efficacy of oxaliplatin or tegafur combined with paclitaxel in the treatment of advanced gastric carcinoma were both confirmed,but patients who received tegafur combined with paclitaxel will have lower risk of developing adverse reactions.